PCAT18: A Potential Drug Target for Proteasome Regulation and Cancer Development

Target Name: PCAT18

NCBI ID: G728606

PCAT18

Other Name(s): LINC01092 | prostate cancer associated transcript 18 | Prostate cancer associated transcript 18

PCAT18: A Potential Drug Target for Proteasome Regulation and Cancer Development

PCAT18 (Proteasome-Accessible Calcium-Transient Activator 18) is a protein that is expressed in various tissues and cells throughout the body. It is a key regulator of the proteasome, a complex protein that helps to break down and remove damaged or unnecessary proteins from the body. PCAT18 is also involved in the regulation of muscle growth and in the development and progression of certain diseases.

In recent years, researchers have been interested in PCAT18 as a potential drug target or biomarker. This is because the regulation of the proteasome is a fundamental process that is involved in many different biological processes, and drugs that target the proteasome have the potential to treat a wide range of diseases.

One of the reasons why PCAT18 is thought to be a promising drug target is that it is involved in the regulation of the proteasome's activity. The proteasome is a complex protein that is made up of multiple subunits that work together to break down and remove damaged or unnecessary proteins from the body. PCAT18 is one of the key regulators of this process, and it is thought to play a key role in the regulation of the proteasome's activity.

In addition, PCAT18 is involved in the regulation of muscle growth and development. muscle growth and development are important processes that are closely regulated by the proteasome. PCAT18 is thought to be involved in the regulation of muscle growth and development by controlling the activity of the proteasome.

Another reason why PCAT18 is thought to be a promising drug target is that it is involved in the development and progression of certain diseases. For example, PCAT18 has been shown to be involved in the development and progression of certain types of cancer, such as lung cancer and ovarian cancer. This suggests that targeting PCAT18 may be a useful way to treat these diseases.

In conclusion, PCAT18 is a protein that is expressed in various tissues and cells throughout the body. It is involved in the regulation of the proteasome, muscle growth and development, and the development and progression of certain diseases. As a result, PCAT18 is thought to be a promising drug target or biomarker. Further research is needed to fully understand the role of PCAT18 in these processes and to develop effective treatments.

Protein Name: Prostate Cancer Associated Transcript 18

The "PCAT18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCAT18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets